Home » Halaven Wins FDA Approval as Third-Line Breast Cancer Treatment
Halaven Wins FDA Approval as Third-Line Breast Cancer Treatment
More than a month before its user fee action date, the FDA has approved Eisai’s late-stage breast cancer treatment Halaven. The drug is indicated to treat metastatic breast cancer in patients who have failed at least two prior chemotherapy regimens, such as anthracycline- and taxane-based therapies. Eisai spokeswoman Judee Shuler did not disclose the drug’s price but noted it reflects the value it provides to patients.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May